Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 7/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.41 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | PLK1 | P53350 | 1/20 | 0.30 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.30 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL902531 | 0.94 | KDM5B (0.41) | CYP11B1CYP11B2KDM5BLRRK2DRD4 | |
| SCHEMBL23109057 | 0.93 | KDM5B (0.41) | CYP11B1CYP11B2KDM5BLRRK2DRD4 | |
| SCHEMBL20053985 | 0.87 | CYP11B2 (0.40) | CYP11B1CYP11B2KDM5BLRRK2DRD4 | |
| SCHEMBL20053992 | 0.81 | CYP11B1 (0.41) | CYP11B1CYP11B2KDM5BLRRK2DRD4 | |
| SCHEMBL23762887 | 0.78 | USP1 (0.33) | KDM5BLRRK2 | |
| SCHEMBL22019786 | 0.78 | DRD4 (0.36) | CYP11B1CYP11B2KDM5BLRRK2DRD4 | |
| SCHEMBL21101279 | 0.74 | LRRK2 (0.37) | LRRK2 | |
| SCHEMBL25189413 | 0.74 | — | — | |
| SCHEMBL13684190 | 0.74 | — | — | |
| SCHEMBL25484494 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3740481-B1 | DIHYDROBENZOFURAN AND INDEN ANALOGS AS CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS INC (US) | 2024-06-26 | — | — | EP | disclosed |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-01-25 | — | — | US | disclosed |
| WO-2024020458-A1 | METHOD OF TREATING ORGAN DISEASES OR DISORDERS WITH ASK1 INHIBITORS | Seal Rock Therapeutics, Inc. (US) | 2024-01-25 | — | — | WO | disclosed |
| US-11858912-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858924-B2 | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides | ASTRAZENECA (SE) | 2024-01-02 | — | — | US | disclosed |
| US-20230399319-A1 | Acylsulfamide Compound and Pharmaceutical Use Therefor | JAPAN TOBACCO INC. (JP) | 2023-12-14 | — | — | US | disclosed |
| US-11827639-B2 | TDO2 and IDO1 inhibitors | GENENTECH, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827639-B2 | TDO2 and IDO1 inhibitors | GENENTECH, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230364070-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ANTARES THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230364070-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ANTARES THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20160304476-A1 | TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME LLC | 2016-10-20 | — | — | US | disclosed |
| US-20160304505-A1 | 2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME LLC | 2016-10-20 | — | — | US | disclosed |
| US-20160186168-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. | 2016-06-30 | — | — | US | disclosed |
| EP-3027754-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | enEvolv, Inc. (US) | 2016-06-08 | — | — | EP | disclosed |
| US-9216173-B2 | 2-Pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-12-22 | — | — | US | disclosed |
| US-20150246923-A1 | 9H-PYRIMIDO[4,5-B]INDOLES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-09-03 | — | — | US | disclosed |
| WO-2015017866-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. (US) | 2015-02-05 | — | — | WO | disclosed |
| US-20140243336-A1 | 2-Pyridyl Carboxamide-Containing Spleen Tyrosine Kinase (SYK) Inhibitors | MERCK SHARP & DOHME LLC | 2014-08-28 | — | — | US | disclosed |
| US-20130040933-A1 | AZAINDOLES AS JANUS KINASE INHIBITORS | CASH BRANDON (US) | 2013-02-14 | — | — | US | disclosed |
| US-20130040933-A1 | AZAINDOLES AS JANUS KINASE INHIBITORS | CASH BRANDON (US) | 2013-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858912-B2 | Heterocyclic compounds | F12, C1R, MRPL21 | CYP11B1 403/4885CYP11B2 431/4885KDM5B 3027/4885 |
| US-20160304505-A1 | 2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | RORA, RORB, RORC | CYP11B1 484/4885CYP11B2 354/4885KDM5B 664/4885 |
| US-11827639-B2 | TDO2 and IDO1 inhibitors | IDO1, TDO2, IDO2 | CYP11B1 854/4885CYP11B2 842/4885KDM5B 250/4885 |
| US-20130040933-A1 | AZAINDOLES AS JANUS KINASE INHIBITORS | JAK1, JAK3, JAK2 | CYP11B1 1246/4885CYP11B2 1125/4885KDM5B 96/4885 |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | CYP11B1 1768/4885CYP11B2 1848/4885KDM5B 3420/4885 |
| US-20230364070-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ERBB2, EGFR, ERBB3 | CYP11B1 2957/4885CYP11B2 2285/4885KDM5B 3405/4885 |
| US-20230399319-A1 | Acylsulfamide Compound and Pharmaceutical Use Therefor | NLRP3, NLRP1, NOD1 | CYP11B1 330/4885CYP11B2 305/4885KDM5B 3998/4885 |
| US-20160304476-A1 | TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | RORB, RORA, RORC | CYP11B1 70/4885CYP11B2 64/4885KDM5B 1680/4885 |
| US-20140243336-A1 | 2-Pyridyl Carboxamide-Containing Spleen Tyrosine Kinase (SYK) Inhibitors | SYK, BTK, LCK | CYP11B1 2710/4885CYP11B2 2472/4885KDM5B 313/4885 |
| US-20150246923-A1 | 9H-PYRIMIDO[4,5-B]INDOLES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | CYP11B1 1473/4885CYP11B2 1972/4885KDM5B 192/4885 |
| US-11858924-B2 | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides | FAP, PREP, CTRL | CYP11B1 4877/4885CYP11B2 4859/4885KDM5B 1019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.